Title |
Quarter Century of Anti-HIV CAR T Cells
|
---|---|
Published in |
Current HIV/AIDS Reports, March 2018
|
DOI | 10.1007/s11904-018-0388-x |
Pubmed ID | |
Authors |
Thor A. Wagner |
Abstract |
A therapy that might cure HIV is a very important goal for the 30-40 million people living with HIV. Chimeric antigen receptor T cells have recently had remarkable success against certain leukemias, and there are reasons to believe they could be successful for HIV. This manuscript summarizes the published research on HIV CAR T cells and reviews the current anti-HIV chimeric antigen receptor strategies. Research on anti-HIV chimeric antigen receptor T cells has been going on for at least the last 25 years. First- and second-generation anti-HIV chimeric antigen receptors have been developed. First-generation anti-HIV chimeric antigen receptors were studied in clinical trials more than 15 years ago, but did not have meaningful clinical efficacy. There are some reasons to be optimistic about second-generation anti-HIV chimeric antigen receptor T cells, but they have not yet been tested in vivo. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 67% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 73 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 14 | 19% |
Student > Bachelor | 14 | 19% |
Student > Master | 13 | 18% |
Researcher | 7 | 10% |
Other | 6 | 8% |
Other | 7 | 10% |
Unknown | 12 | 16% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 14 | 19% |
Immunology and Microbiology | 14 | 19% |
Agricultural and Biological Sciences | 12 | 16% |
Medicine and Dentistry | 8 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 7% |
Other | 6 | 8% |
Unknown | 14 | 19% |